Winston Churchill’s cerebrovascular disease: small vessels with big implications
Author(s) -
David J. Werring
Publication year - 2018
Publication title -
journal of the royal society of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.38
H-Index - 81
eISSN - 1758-1095
pISSN - 0141-0768
DOI - 10.1177/0141076818796194
Subject(s) - data science , computer science , medicine
Winston Churchill is among the most significant political figures in British, European and world politics in the 20th century. Best known for his leadership of Britain in World War II, and for his extraordinary political and personal determination, Churchill faced some of his greatest challenges from the consequences of cerebral small vessel disease, between 1949 and his death in 1965. In the first three of six articles in the Journal of the Royal Society of Medicine, Scadding and Vale provide clear and detailed accounts, taken from multiple contemporary sources, of Churchill’s strokes in 1949 and 1953, and other manifestations of cerebrovascular disease from 1950 to 1952. The articles elegantly remind us of the characteristic clinical features of ischaemic strokes due to cerebral small vessel disease (where occlusion of a small perforating artery typically causes a distinct ‘lacunar’ clinical syndrome, most commonly a ‘pure motor stroke’ with hemiparesis affecting the face, arm and leg) but also highlight important gaps in our current knowledge and treatments for this form of cerebrovascular disease. Small vessel occlusion accounts for about one in four ischaemic strokes; although the prognosis for recovery is generally good, a proportion of patients progress acutely in the first few days after onset, particularly in the domain of motor function. This notable clinical feature of small vessel strokes remains a clinical and research challenge today. Winston Churchill’s behaviour and account at the time of onset of the first stroke in 1949 suggest that the symptoms progressed over a matter of hours (first removing the ring, then mentioning a cramping feeling, then having writing difficulty). The progressive onset is typical of small vessel occlusion, and the clinical syndrome suggested involvement of the internal capsule and thalamus. The second stroke in 1953 also showed progressive and fluctuating onset in the first 24 h, with the involvement of the face, arm and leg indicating a ‘pure motor stroke’ due to a lesion in the corticospinal projections within the posterior limb of the internal capsule. This characteristic progression and fluctuation in the first day or so from the onset of small vessel occlusion are still not at all well understood. Suggested mechanisms include propagation of thrombosis, haemodynamic factors, excitotoxicity, inflammation, oedema or conduction block. Some evidence suggests that patients with branch artery atherosclerotic disease affecting the parent artery (e.g. the proximal middle cerebral artery from which the lenticulostriate perforators arise) with proximal occlusion at a perforator origin are more likely to clinically progress than those with more distal occlusion of a perforating artery; this is hypothesised to result from either thrombus propagation along the perforator (with sequential progressive occlusion of lateral smaller branches) or reduction in perfusion (causing ischaemia spreading from the distal to proximal tissue irrigated by the perforating artery). Some evidence from perfusion magnetic resonance imaging supports a role for haemodynamic failure in progressive lacunar syndromes. Another hypothesis is that peri-infarct oedema might exert pressure on neighbouring perforating branches, causing them to occlude, thus extending the infarct. These mechanisms are not just of academic interest, because they highlight the persisting gaps in our understanding and a lack of specific treatments. If thrombus propagation is important, then acute anticoagulation or thrombolysis might be reasonable in progressive small vessel stroke. However, although intravenous thrombolysis is considered beneficial in all types of ischaemic stroke, there is limited evidence of specific efficacy in small vessel occlusion. Endothelial dysfunction and platelet aggregation might logically respond to antiplatelet therapy, while haemodynamic failure might require measures Journal of the Royal Society of Medicine; 2018, Vol. 111(9) 314–315
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom